Jun 16, 2020
IDEAYA Announces Proposed Public Offering of Common Stock
Jun 16, 2020
IDEAYA and GSK Announce a Broad Partnership in Synthetic Lethality, an Emerging Field in Precision Medicine Oncology
Jun 11, 2020
IDEAYA Biosciences Selected to Join Russell 3000® Index
Jun 08, 2020
IDEAYA Announces Nomination of Development Candidate, IDE397, for MAT2A Synthetic Lethality Program Targeting MTAP-Deletion Patient Population
May 19, 2020
IDEAYA Biosciences to Participate in Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020
May 15, 2020
IDEAYA Biosciences Announces AACR Abstracts for IDE196 Targeting GNAQ/11 Tumors and Preclinical MAT2A Synthetic Lethality Program
Apr 21, 2020
IDEAYA Biosciences Announces Addition of Julie Patel as Vice President, Human Resources, Enhancing its Leadership Team
Mar 18, 2020
IDEAYA and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Clinical Combination of IDE196 and Binimetinib in Solid Tumors Harboring GNAQ or GNA11 Hotspot Mutations
Mar 18, 2020
IDEAYA Biosciences Announces IDE196 Monotherapy Phase 2 Dose Selection and Clinical Program Update
Mar 11, 2020
IDEAYA Biosciences and Cancer Research UK Announce Expanded Research Collaboration for PARG, a DDR-Based Synthetic Lethality Target, Evaluating DNA Replication Vulnerabilities
Jan 15, 2020
IDEAYA Biosciences Announces Synthetic Lethality Research Highlights and Target Milestones for 2020
Jan 10, 2020
IDEAYA Biosciences and Boston Children's Hospital Collaborate on Preclinical Evaluation of IDE196 for Sturge Weber Syndrome - a Rare Disease Associated with Genetic Mutation of GNAQ
Jan 06, 2020
IDEAYA Biosciences to Present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020
Dec 18, 2019
IDEAYA Biosciences Appoints Wendy Yarno to its Board of Directors
Dec 09, 2019
IDE196 Program Updates: Targeting Initiation of Potentially Registration-Enabling Phase 2 Single-Arm Monotherapy Trial in MUM and Introduction of Tablet Formulation in Q1 2020
Nov 20, 2019
Phase 1/2 Clinical Trial Data for IDE196 Presented at Society for Melanoma Research Congress
Nov 15, 2019
Phase 1/2 Clinical Trial Progress for IDE196 to be Presented at Society for Melanoma Research Congress
Nov 13, 2019
IDEAYA Biosciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update
Nov 05, 2019
IDEAYA Biosciences Announces Leadership Updates in Research Organization
Oct 31, 2019
IDEAYA Biosciences Reports End-of-Phase 1 Meeting with FDA for IDE196 Confirms Acceptability of Single-Arm Trial Design for Potential Phase 2 Registration-Enabling Study in Metastatic Uveal Melanoma